GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
GO:0006650 | Colorectum | AD | glycerophospholipid metabolic process | 83/3918 | 306/18723 | 5.40e-03 | 3.55e-02 | 83 |
GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
GO:00066441 | Colorectum | SER | phospholipid metabolic process | 79/2897 | 383/18723 | 3.94e-03 | 3.24e-02 | 79 |
GO:00480171 | Colorectum | SER | inositol lipid-mediated signaling | 42/2897 | 182/18723 | 4.36e-03 | 3.49e-02 | 42 |
GO:00450171 | Colorectum | SER | glycerolipid biosynthetic process | 55/2897 | 252/18723 | 4.47e-03 | 3.56e-02 | 55 |
GO:00480151 | Colorectum | SER | phosphatidylinositol-mediated signaling | 41/2897 | 178/18723 | 4.97e-03 | 3.86e-02 | 41 |
GO:00066501 | Colorectum | SER | glycerophospholipid metabolic process | 64/2897 | 306/18723 | 6.41e-03 | 4.60e-02 | 64 |
GO:0008654 | Colorectum | FAP | phospholipid biosynthetic process | 54/2622 | 253/18723 | 8.88e-04 | 9.08e-03 | 54 |
GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
GO:0046474 | Colorectum | FAP | glycerophospholipid biosynthetic process | 44/2622 | 211/18723 | 3.98e-03 | 2.76e-02 | 44 |
GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3C2B | SNV | Missense_Mutation | novel | c.2684N>A | p.Pro895Gln | p.P895Q | O00750 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-37-3789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | | c.3325N>T | p.Gly1109Trp | p.G1109W | O00750 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-37-4135-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | | c.1597G>T | p.Val533Phe | p.V533F | O00750 | protein_coding | deleterious(0) | benign(0.172) | TCGA-37-5819-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | rs747728370 | c.2701N>T | p.Arg901Cys | p.R901C | O00750 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-56-7221-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | novel | c.4407N>T | p.Leu1469Phe | p.L1469F | O00750 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-60-2706-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | | c.3623A>G | p.His1208Arg | p.H1208R | O00750 | protein_coding | deleterious(0) | possibly_damaging(0.679) | TCGA-60-2707-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
PIK3C2B | SNV | Missense_Mutation | | c.349N>G | p.Pro117Ala | p.P117A | O00750 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-60-2708-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
PIK3C2B | SNV | Missense_Mutation | rs773548781 | c.1351N>T | p.Arg451Cys | p.R451C | O00750 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-66-2800-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | | c.4045C>T | p.Arg1349Trp | p.R1349W | O00750 | protein_coding | deleterious(0.01) | possibly_damaging(0.549) | TCGA-77-8148-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PIK3C2B | SNV | Missense_Mutation | | c.683N>T | p.Tyr228Phe | p.Y228F | O00750 | protein_coding | tolerated_low_confidence(0.25) | benign(0.003) | TCGA-85-6560-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BYL719 | ALPELISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BAY80-6946 | COPANLISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0941 | PICTILISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | PKI-587 | GEDATOLISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BEZ235 | DACTOLISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 178102328 | PI-103 | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0980 | APITOLISIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BGJ398 | INFIGRATINIB | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 252827496 | | |
5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | XL-765 | VOXTALISIB | |